RPS launching new pharmacogenomic resource for all prescribers

The Royal Pharmaceutical Society (RPS) is launching a resource to help prescribers develop their pharmacogenomic competence and standardise pharmacogenomic education across professions. 

It is currently consulting on the resource, which ultimately aims to improve patient outcomes through medicines optimisation.

Pharmacogenomics is the study of how genetic variation influences drug response, to enable safer and more effective prescribing.

In 2025, the RPS were commissioned by NHS England to develop this resource as the number of pharmacogenomic tests available within mainstream clinical practice across the UK increased.

Related Article: Beyond the scales: reframing eating disorder recognition in primary care

The consultation will also explore whether new pharmacogenomic-specific competencies are required or if changes should be recommended to the current Competency Framework for all Prescribers.

The competencies listed within the recourse are split into two domains: skills relating to the consultation, and skills relating to prescribing governance.

Domain one includes assessing the patient, identifying evidence-based treatment options, prescribing, providing information and monitoring the outcome.

While domain two focuses on prescribing safely and professionally, improving prescribing practice and prescribing as part of a team.

The RPS is seeking feedback on the draft resource from:

• Prescribers already using pharmacogenomics;
• Prescribers interested in using pharmacogenomics;
• Organisations employing or representing prescribers;
• Individuals and organisations familiar with the Competency Framework for all Prescribers.

Those wanting to contribute should read the draft resource and then complete the online consultation questionnaire. The survey will be open until Friday 9 January 2026.  

Related Article: Sharp rise in diabetes cases prompts call for better postnatal support

Dr Sophie Harding, consultant pharmacist for Genomics and Pharmacogenomics and lead author, said: ‘Pharmacogenomics has the potential to improve patient outcomes by ensuring that prescribing is better targeted, more personalised and more effective.

‘We want to develop a resource that is practical, high-quality and useful for every prescriber, regardless of setting, profession or level of experience. Your feedback will help us shape a tool that reflects real-world practice and supports safe, evidence-based clinical decision-making.’

A recent report by Community Pharmacy England (CPE) highlighted the potential of pharmacogenomics to revolutionise the role of community pharmacies.

‘In the future, pharmacists may be able to interpret pharmacogenomic data to guide medication selection and dosing, minimising adverse effects and optimising treatment outcomes for individuals.

Related Article: Premises renewals to be shifted into myGPhC portal

‘Community pharmacies are ideally placed to educate patients about pharmacogenomic testing, ensuring informed decision-making and privacy,’ the report said. However, this can only be achieved ‘with appropriate training’, it added.

In September, the RPS also launched a new e-learning module to help healthcare professionals manage polypharmacy and reduce the risks linked to drug interactions. This included content on pharmacogenomics and AI in prescribing.